Bristol-Myers Squibb appoints acting chief financial officer

Bristol-Myers Squibb revealed this week that it has appointed Charles Bancroft as its acting chief financial officer from January 1st 2010.

This is due to the announcement that Jean-Marc Huet, the firm’s current chief financial officer and executive vice-president, will leave his post at the end of 2009.

James Cornelius, chairman and chief executive officer of Bristol-Myers Squibb, commented: “The board of directors and I are grateful to Jean-Marc for his strategic work in rapidly and successfully solidifying our balance sheet.”

Mr Bancroft, who joined Bristol-Myers Squibb in 1984, has taken on increasing responsibilities over the years within its finance department.

He was most recently vice-president of finance for the organisation’s global biopharmaceutical business and will now report to the company’s chief operating officer and president Lamberto Andreotti.

Meanwhile, last week Bristol-Myers Squibb and its pharmaceutical partner Pfizer announced the submission of a regulatory approval request for the venous thromboembolism (VTE) drug apixaban in Europe.